The efficacy and safety of mirabegron in treating OAB: a systematic review and meta-analysis of phase III trials
Authors:
- 30 July 2013
- journal article
- review article
- Published by Springer Nature in International Urology and Nephrology
- Vol. 46 (1) , 275-284
Abstract
Mirabegron, a potent and selective β3-adrenoceptor agonist, has been developed for the treatment of overactive bladder (OAB). We carried out a systematic review and meta-analysis to assess the efficacy and safety of the drug for treating OAB. A literature review was performed to identify all published randomized double-blind, placebo-controlled phase III trials of mirabegron for the treatment of OAB. The search included the following databases: MEDLINE, EMBASE and the Cochrane Controlled Trials Register. The reference lists of the retrieved studies were also investigated. A systematic review and meta-analysis of phase III trials were conducted. Four publications involving a total of 5,761 patients were used in the analysis, including four phase III RCTs that compared mirabegron with placebo. We found that mirabegron was effective in treating OAB in our meta-analysis. Co-primary efficacy end points: the mean number of incontinence episodes per 24 h (the standardized mean difference (SMD) = −0.44, 95 % confidence interval (CI) −0.59 to −0.29, p < 0.00001); the mean number of micturitions per 24 h (SMD = −0.62, 95 % CI −0.80 to −0.45, p < 0.00001) and key secondary efficacy end points: mean volume voided per micturition; mean number of urgency episodes per 24 h indicated that mirabegron was more effective than the placebo. Safety assessments included common treatment-emergent adverse events (TEAEs) [OR 1.10, 95 % CI 0.93–1.31, p = 0.25), hypertension, cardiac arrhythmia TEAEs, urinary retention and discontinuations due to adverse event indicated that mirabegron was well tolerated. This meta-analysis indicates that mirabegron to be an effective and safe treatment for OAB symptoms with a low occurrence of side effects. It offers promise as an effective oral agent for the treatment of OAB with a distinct efficacy/tolerability balance.Keywords
This publication has 22 references indexed in Scilit:
- Randomized Double-blind, Active-controlled Phase 3 Study to Assess 12-Month Safety and Efficacy of Mirabegron, a β3-Adrenoceptor Agonist, in Overactive BladderEuropean Urology, 2013
- Low persistence of anticholinergic drug use in SwedenEuropean Journal of Clinical Pharmacology, 2010
- β−Adrenergic receptor subtype expression in myocyte and non-myocyte cells in human female bladderCell and tissue research, 2010
- Patient‐reported reasons for discontinuing overactive bladder medicationBJU International, 2010
- Effect of (R)-2-(2-Aminothiazol-4-yl)-4′-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} Acetanilide (YM178), a Novel Selective β3-Adrenoceptor Agonist, on Bladder FunctionThe Journal of Pharmacology and Experimental Therapeutics, 2007
- Population-Based Survey of Urinary Incontinence, Overactive Bladder, and Other Lower Urinary Tract Symptoms in Five Countries: Results of the EPIC StudyEuropean Urology, 2006
- Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladderBritish Journal of Pharmacology, 2006
- The standardisation of terminology of lower urinary tract function: Report from the standardisation sub‐committee of the International Continence SocietyNeurourology and Urodynamics, 2002
- Evidence for β3-Adrenoceptor Subtypes in Relaxation of the Human Urinary Bladder Detrusor: Analysis by Molecular Biological and Pharmacological MethodsThe Journal of Pharmacology and Experimental Therapeutics, 1999
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986